Clinical Trial

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Trial Details
NCT Number NCT07025889
Lead Sponsor Ruijin Hospital
Collaborators: Shanghai Jiao Tong University School of Medicine
Conditions Gastric Cancer
Enrollment 55 participants
Start Date 2025-06-02
Primary Completion 2026-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-18